Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746466 | 0.89 | GRIN1 (0.61) | HRH3CYP2D6HRH1GRIN1GRIN2B | |
| SCHEMBL3965085 | 0.89 | GRIN1 (0.61) | HRH3CYP2D6HRH1GRIN1GRIN2B | |
| SCHEMBL3970687 | 0.89 | GRIN1 (0.61) | HRH3CYP2D6HRH1GRIN1GRIN2B | |
| SCHEMBL21126509 | 0.81 | GRIN1 (0.58) | GRIN1GRIN2BCA2CA5A | |
| SCHEMBL17583857 | 0.80 | CA2 (0.46) | HRH3CYP2D6HRH1GRIN1GRIN2B | |
| SCHEMBL18983590 | 0.79 | HRH3 (0.59) | HRH3CYP2D6HRH1 | |
| SCHEMBL7177129 | 0.79 | CSF1R (0.42) | HRH3CYP2D6MAOAMAOB | |
| SCHEMBL7175987 | 0.79 | CSF1R (0.42) | HRH3CYP2D6MAOAMAOB | |
| SCHEMBL7176955 | 0.79 | CSF1R (0.42) | HRH3CYP2D6MAOAMAOB | |
| SCHEMBL3750778 | 0.78 | FFAR1 (0.53) | HRH3MAOAMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2020-03-03 | — | — | US | disclosed |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2020-03-03 | — | — | US | disclosed |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-01-03 | — | — | US | disclosed |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-01-03 | — | — | US | disclosed |
| EP-3124472-B1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-07-25 | — | — | EP | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| EP-3124472-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2017-02-01 | — | — | EP | disclosed |
| EP-3124472-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2017-02-01 | — | — | EP | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| EP-2797888-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2014-11-05 | — | — | EP | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013097224-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013097224-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | HRH3 596/4885CYP2D6 4239/4885HRH1 482/4885 |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HRH3 3151/4885CYP2D6 3301/4885HRH1 2939/4885 |
| US-20190000857-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | HRH3 3165/4885CYP2D6 3560/4885HRH1 3015/4885 |
| US-10576087-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BRAF, RAF1, ARAF | HRH3 3151/4885CYP2D6 3301/4885HRH1 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.